{"id":"bd-mdi-40-g","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Oral thrush"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1588467","moleculeType":"Small molecule","molecularWeight":"332.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BD MDI 40 µg contains a medication called fluticasone propionate, which is a corticosteroid that reduces inflammation in the airways. This helps to prevent symptoms such as wheezing, coughing, and shortness of breath. By reducing inflammation, BD MDI 40 µg helps to improve lung function and overall quality of life for people with asthma or COPD.","oneSentence":"BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:34.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of COPD"}]},"trialDetails":[{"nctId":"NCT03847896","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2019-03-20","conditions":"Asthma","enrollment":1001},{"nctId":"NCT02105012","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-04-01","conditions":"Asthma","enrollment":147}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PT008"],"phase":"phase_2","status":"active","brandName":"BD MDI 40 µg","genericName":"BD MDI 40 µg","companyName":"Pearl Therapeutics, Inc.","companyId":"pearl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}